Lupin Limited — Investor Meet, 12-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Lupin delivered strong Q3 FY26 results with Sales at INR 7,100.5 Cr, up 26% YoY, and EBITDA at INR 2,209.5 Cr, surging 62% YoY, achieving a 31.1% margin. Net Income rose 38% YoY to INR 1,175.6 Cr (includes INR 426.6 Cr exceptional items). North America sales soared 52% and India grew 6%. Key launches include gRisperdal Consta® and US FDA approval for biosimilar Armlupeg. The company continues to strengthen its complex generics and biosimilar pipeline, with positive regulatory compliance updates across multiple facilities. Management highlights consistent margin improvement and strategic partnerships for future growth.